Home Page: Annals of Allergy, Asthma Immunology

Time 2021-05-22 14:14:47

Web Name: Home Page: Annals of Allergy, Asthma Immunology

WebSite: http://www.annallergy.org

ID:178303

Keywords:

Annals,Page,Home,

Description:

Recent Development on the use of SLIT tablets for Allergic RhinitisProfessor of Medicine Susan Waserman, Anita Shah, Ernie AvillaDOI: https://doi.org/10.1016/j.anai.2021.05.020Publication stage: In Press Journal Pre-ProofAnnals of Allergy, Asthma ImmunologyPreviewFull-Text HTMLPDFxAllergic rhinitis (AR), which can occur with or without conjunctivitis (C), is an IgE-mediated inflammatory condition that causes symptoms of sneezing, nasal congestion, rhinorrhea, and nasal itch.1,2 It is estimated that 10-30% of the population is affected by AR which can have a considerable impact on quality of life (Figure 1).1 Allergic Rhinitis and its Impact on Asthma guidelines have shown that the severity of symptoms can be measured in clinical practice using a visual analogue scale (VAS), a quantitative tool which can guide decisions on treatment.Dupilumab in the Treatment of Nasal Polyposis: A Retrospective, Real-world StudySomaira Nowsheen, Jared I DarveauxDOI: https://doi.org/10.1016/j.anai.2021.05.018Publication stage: In Press Journal Pre-ProofAnnals of Allergy, Asthma ImmunologyPreviewFull-Text HTMLPDFxNasal polyposis is frequently associated with chronic rhinosinusitis, high symptom burden and poor quality of life. Options for treatment resistant disease include aspirin desensitization, recurring systemic corticosteroid use and sinus surgery.1 Dupilumab is a human monoclonal antibody that blocks signaling of interleukin-4 and interleukin-13. These cytokines drive allergic diseases such as atopic dermatitis, asthma and nasal polyposis, for which dupilumab is an approved therapy.2 In this retrospective cohort study, our aims were to assess real world efficacy and safety of dupilumab for treatment of nasal polyposis.Exposure to species of Vespidae in the urbanized areas of New Orleans, LouisianaJohn C Carlson, Mark S FoxDOI: https://doi.org/10.1016/j.anai.2021.05.014Publication stage: In Press Journal Pre-ProofAnnals of Allergy, Asthma ImmunologyOpen AccessPreviewFull-Text HTMLPDFxThe venom of social Hymenoptera is an important trigger for anaphylactic events. Currently available extracts for testing venom-allergic patients were standardized prior to recent changes in urbanization and introduction of invasive species. Failure to test for all relevant species may be one reason that these tests are unable to identify the cause of wasp venom allergies in some patients.[1] In addition, cross-reactivity between species in the Vespidae (genera Vespa, Vespula, Dolichovespula, Polistes, Mischocyttarus) may cause positive tests in patients for whom the primary sensitization was not one of the species tested.How our treatment of asthma has changed over the last half centuryHarold S NelsonDOI: https://doi.org/10.1016/j.anai.2021.05.016Publication stage: In Press Journal Pre-ProofAnnals of Allergy, Asthma ImmunologyPreviewFull-Text HTMLPDFxAt the close of the 1960s asthma treatment was quite simple. For chronic maintenance treatment there were tablets containing the sympathomimetic ephedrine, the methylxanthine theophylline, a barbiturate or hydroxyzine to offset the stimulatory side effects of ephedrine and in some preparations an expectorant. Other chronic medications included the expectorants iodine and glyceryl guaiacolate administered singly, the oral corticosteroids prednisone and methyl prednisolone, and the long acting inhaled steroid dexamethasone, which was fully active systemically.Seroconversion Following COVID-19 Vaccination in Immune Deficient PatientsJacqueline Squire, Dr. Avni JoshiDOI: https://doi.org/10.1016/j.anai.2021.05.015Publication stage: In Press Journal Pre-ProofAnnals of Allergy, Asthma ImmunologyPreviewFull-Text HTMLPDFxSafety and efficacy are two major drivers for any vaccination strategy and have come to the forefront in the setting of SARS-CoV-2 vaccination. Patients with underlying primary or secondary immunodeficiencies have variable response to vaccination, but inactivated or nonviable vaccines are generally considered safe in immune deficient patients.[1] The efficacy of inactivated vaccines is variable in patients with humoral immune deficiencies, many can mount a protective T-cell dependent antibody response to protein conjugated vaccines, except for patients with congenital agammaglobulinemia such as X-linked agammaglobulinemia (XLA) who may lack the ability to mount any antibody response. About the Journal Annals of Allergy, Asthma Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of the Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency. About ACAAI The American College of Allergy, Asthma Immunology is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy and research. Access this journal on ScienceDirect Visit ScienceDirect to see if you have access via your institution. MOC-CME Reviews What do allergists in practice need to know about non–IgE-mediated food allergiesUnlike immunoglobulin (Ig) E–mediated food allergy (FA), in which 1 pathophysiological mechanism explains 1 disease process, non-IgE FA encapsulates a number of disease states caused by different mechanisms but unified in their ability to cause gastrointestinal inflammation. The commonest non–IgE-mediated disorders encountered and managed by allergists include food protein–induced allergic proctocolitis (FPIAP), eosinophilic esophagitis (EoE), food protein–induced enteropathy (FPE), and food protein–induced enterocolitis syndrome (FPIES). Knowledge of celiac disease (CD) is beyond the scope of this review, and is briefly discussed in supplementary section.Read More We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.

TAGS:Annals Page Home 

<<< Thank you for your visit >>>

Hot Websites